Management of Renal Hypertension pp 1-39 | Cite as
Modern Drug Therapy
Abstract
Renal hypertension is not easy to define. Many forms of acute and chronic renal parenchymal and vascular disease may be associated with hypertension. Causation is more difficult to prove. ‘Essential’ hypertension may affect at least 20% of the adult population in Western societies and as a result will frequently coexist with other diseases. Furthermore, sustained hypertension, of whatever cause, results in impaired renal function. In the strictest sense, causation may only be proved if the renal disorder can be shown to precede the development of hypertension, and if the hypertension resolves after removal of the offending kidney or resolution of the renal disorder. This is seldom possible. Hypertension may persist even after removal of the primary renal cause (for example, renal artery stenosis) as a result of irreversible damage in the contralateral kidney or structural changes in resistance vessels. Even in mild uncomplicated essential hypertension, there is evidence to suggest that the primary ‘lesion’ lies in the kidney1. There is clearly a wide spectrum of clinical conditions in which renal perfusion, renal function and systemic blood pressure are closely interrelated.
Keywords
Renal Artery Hypertensive Patient Diabetic Nephropathy Angiotensin Converting Enzyme Renal Artery StenosisPreview
Unable to display preview. Download preview PDF.
References
- 1.de Wardener, H.E. and MacGregor, G.A. (1982). The natriuretic hormone and essential hypertension. Lancet., 1, 1450–54PubMedCrossRefGoogle Scholar
- 2.Rudnick, K.V., Sackett, D.L., Hirst, S. and Holmes, C. (1977). Hypertension in a family practice. Can. Med. Assoc. J., 117, 492–7PubMedGoogle Scholar
- 3.Danielsen, H., Kornerup, H.J., Olsen, S.O. and Posburg, V. (1983). Arterial hypertension in chronic glomerulonephritis. An analysis of 310 cases. Clin. Nephrol. 19, 284–7PubMedGoogle Scholar
- 4.Walker, G.G., Bender, W.L. (1984). Management of endstage renal disease. In Harvey A. McG, Johns, R.J., McKusick, V.A., Owens, A.H., Ross, R.S. The Principles and Practice of Medicine, pp 136–148. Connecticut: Appleton-Century-CroftsGoogle Scholar
- 5.Dollery, C.T., Beilin, L.J., Bulpitt, C.J., Coles, E.C., Johnson, B.F., Munro-Faure, A.D., Turner, S.C. (1977) Initial care of hypertensive patients. Influence of different types of clinical records. Br. Heart J. 39, 181–5PubMedCrossRefGoogle Scholar
- 6.Siamopoulos, K., Sellars, L., Mishra, S.C., Essenhigh, D.M., Robson, V., Wilkinson, R. (1983). Experience in the management of hypertension with unilateral chronic pylonephritis: results in nephrectomy in selected patients. Q. J. Med. 207, 349–62Google Scholar
- 7.Murray, T., Goldberg, M. (1975). Chronic interstitial nephritis: etiologic factors. Ann. Intern. Med. 82, 453–9PubMedGoogle Scholar
- 8.Robertson, J.I.S., Morton J.J., Tillman, D.M., Lever, A.F. (1986). The pathophysiology of renovascular hypertension. J. Hypertension., 4, (Suppl. 4), 95–103Google Scholar
- 9.Goldblatt, H., Lynch, R.F., Hanzai, R.F., Summerville, W. (1934). Studies on experimental hypertension, production of persistent elevation of systolic blood pressure by means of renal ischaemia. J. Exp. Med. 59, 347–79PubMedCrossRefGoogle Scholar
- 10.Bulpitt, C.J., Beevers, D.G., Butler, A., Coles, E.C., Hunt, D., Munro-Faure, A.D., Newson, R.B., O’Riordan, P.W., Petrie, J.C., Rajagopalan, B., Rylance, P.B., Twallin, G., Webster, J., Dollery, C.T. (1986). The survival of treated hypertensive patients and their causes of death: a report from the DHSS hypertensive care computing project (DHCCP). J. Hypertension., 4, 93–9CrossRefGoogle Scholar
- 11.Veterans Administration Cooperative Study Group on Antihypertensive Agents, Effects of treatment on morbidity in hypertension—results in patients with diastolic blood pressures averaging 115 through 129mmHg. (1970). J. Am. Med. Assoc. 213, 1143–52CrossRefGoogle Scholar
- 12.Veterans Administration Cooperative Study Group on AntihypertensiveAgents, Effects of treatment on morbidity in Hypertension, ii. Results in patients with diastolic blood pressure averaging 90 through 114mmHg. (1970). J. Am. Med. Assoc., 213, 1143–52CrossRefGoogle Scholar
- 13.Smith, D.E., Odel, H.M. and Kernohan, J.W. (1950). Causes of death in hypertension. Am. J. Med. 9, 516–27PubMedCrossRefGoogle Scholar
- 14.Bulpitt, C.J., Breckenridge, A. (1976). Plasma urea in hypertensive patients. Br. Heart J. 38, 689–94PubMedCrossRefGoogle Scholar
- 15.Sugimoto, T., Rosansky, S.J. (1984). The incidence of treated end stage renal disease in the Eastern United States: 1973–79. Am. J. Public Health., 74, 14–17PubMedCrossRefGoogle Scholar
- 16.Wing, A.J., Broyer, M., Brunner, F.P., Challah, S., Donckerwolke, R.A., Gretz, N., Jacobs, C., Kramer, P., Selwood, N.H. (1983). Combined report on regular dialysis and transplantation in Europe, XII 1982. Proc. Eur. Dialy. Transplant. Assoc. — Eur. Renal Assoc. 20, 5–75Google Scholar
- 17.Brunner, F.P., Broyer, M., Brynger, H., Challah, S., Fassbinder, W., Oules, R., Rizzoni, G., Selwood, N.H., Wing, A.J. (1985). Combined report on regular dialysis and transplantation in Europe, XV 1984. Proc. Eur. Dialy. Transplant. Assoc. — Eur. Renal Assoc. 22, 5–53Google Scholar
- 18.Nanra, R.S. Druginduced renal disease (1986). Med. Int. 2nd Series., 33, 1366–76Google Scholar
- 19.Shiel, A., Stewart, J., Johnson, J. (1969). Community treatment of endstage renal failure by dialysis and transplantation from cadaver donors. Lancet., 2, 917–20CrossRefGoogle Scholar
- 20.Kimmelstiel, P., Wilson, C. (1936). Intercapillary lesions in the glomeruli of the kidney. Am. J. Pathol. 12, 83–97PubMedGoogle Scholar
- 21.Parving, H-H., Andersen, A.R., Smidt, U.M., Svendsen, P.A. (1983). Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet., 1, 1175–8PubMedCrossRefGoogle Scholar
- 22.Taguma, Y., Kitamoto, Y., Futaki, G., Ueda, H., Monma, H., Ishizaki, M., Takahashi, H., Sekino, H., Sasaki, Y. (1985). Effect of captopril on heavy proteinuria in azotemic diabetics. N. Engl. J. Med. 313, 1617–20PubMedCrossRefGoogle Scholar
- 23.Hommel, E., Parving, H.H., Mathiesen, E., Edsberg, B., Nielsen, M.D., Giese, J. (1986). Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br. Med. J. 293, 467–70CrossRefGoogle Scholar
- 24.Bjorck, S., Nyberg, G., Mulec, H., Granerus, G., Herlitz, H., Aurell, M. (1986). Beneficial effects of angiotensin converting enzyme inhibitors on renal function in patients with diabetic nephropathy. Br. Med. J. 293, 471–4CrossRefGoogle Scholar
- 25.Shapiro, A.P., Perez-Stable, E., Moutsos, S.E. (1965). Coexistence of renal arterial hypertension and diabetes mellitus. J. Am. Med. Assoc. 192, 813–16CrossRefGoogle Scholar
- 26.Gabriel, R. (1986). Time to scrap creatinine clearance?Br. Med. J. 293, 1119–20Google Scholar
- 27.Calabrese, G., Vagelli, G. and Cristofano, C. (1982). Behaviour of arterial pressure in different stages of polycystic kidney disease. Nephron, 32, 207–8PubMedCrossRefGoogle Scholar
- 28.Mitcheson, H.D., Williams, G., Castro, J.E. (1977). Clinical aspects of polycystic disease of the kidneys. Br. Med. J. 1, 1196–9PubMedCrossRefGoogle Scholar
- 29.Reeders, S.T., Breuning, M.H., Corney, G., Jeremiah, S.J., Meera Khan, P., Davies, K.E., Hopkinson, D.A., Pearson, P.L., Weatherall, D.J. (1986). Two genetic markers closely linked to adult polycystic kidney disease on chromosome 16. Br. Med. J. 292, 851–2CrossRefGoogle Scholar
- 30.Duggan, M.L. (1963). Acute renal infarction. J. Urol. 90, 669–776Google Scholar
- 31.Lessman, R.K., Johnson, S.F., Cobura, J.W., Kaufman, J.S. (1978). Renal artery embolism: Clinical features and long term follow up of 77 cases. Ann. Intern. Med. 89, 477–82PubMedGoogle Scholar
- 32.Elkik, F., Corvol, P., Idatte, J.M., Menard, J. (1984). Renal segmental infarction: a cause of reversible malignant hypertension. J. Hypertension., 2, 149–56CrossRefGoogle Scholar
- 33.Rudnick, M.R., Maxwell, M.H. (1984). Diagnosis of renovascular hypertension: limitations of renin assays. In Narins, R.G. (ed.) Controversies in Nephrology and Hypertension, pp 128–129. New York: Churchill LivingstoneGoogle Scholar
- 34.Sellars, L., Shore, A.C., Wilkinson, R. (1985). Renal vein renin studies in renovascular hypertension—do they really help? J. Hypertension., 3, 177–81CrossRefGoogle Scholar
- 35.Mackay, A., Boyle, P., Brown, J.J., Cumming, A.M.M., Forrest, H., Graham, A.G., Lever, A.F., Robertson, J.I.S., Semple, P.F. (1983). The decision on surgery in renal artery stenosis. Q. J. Med. 207, 363–81Google Scholar
- 36.Geyskes, G.G., Puylaert, C.B.A., Oei, H.Y., Mees, E.J.D. (1983). Follow up study of 70 patients with renal artery stenosis treated by percutaneous transluminal dilatation. Br. Med. J. 287, 333–6CrossRefGoogle Scholar
- 37.Pickering, T.G., Sos, T.A., Vaughan, E.D., Case, D.B., Sealey, J.E., Harshfield, G.A., Laragh, J.H. (1984). Predictive value and changes of renal secretion in hypertensive patients with unilateral renovascular disease undergoing successful renal angioplasty. Am. J. Med. 76, 398–404PubMedCrossRefGoogle Scholar
- 38.Eyler, W.R., Clark, M.D., Garman, J.E., Rian, R.L., Meininger, D.E. (1962). Angiography of the renal areas including a comparative study of renal arterial stenosis in patients with and without hypertension. Radiology., 78, 879–91PubMedGoogle Scholar
- 39.Holley, K.E., Hunt, J.C., Brown, A.L. (1964). Renal artery stenosis—a clinical pathological study in normotensive and hypertensive patients. Am. J. Med. 37, 14–22PubMedCrossRefGoogle Scholar
- 40.Isles, C.J. (1987). Personal communicationGoogle Scholar
- 41.Sos, T.A., Pickering, T.G., Sniderman, K., Saddekin, S., Case, D.B., Silane, M.F., Vaughan, E.D. and Laragh, J.H. (1983). Percutaneous transluminal renal angioplasty in renovascular hypertension due to atheroma or fibromuscular dysplasia. N. Engl. J. Med. 309, 274–9PubMedCrossRefGoogle Scholar
- 42.Schreiber, M.J., Novick, A.C., Pohl, M.A. (1981). The natural history of atherosclerotic and fibrous renal artery disease. Kidney Int., 19, 175Google Scholar
- 43.Hunt, J.C., Strong, C.G. (1973). Renovascular hypertension—mechanisms, natural history and treatment. Am. J. Cardiol. 32, 562–74PubMedCrossRefGoogle Scholar
- 44.Pickering, T.G., Sos, T.A., Orenstein, A., Laragh, J.H. (1986). 11th Scientific Meeting of International Society of Hypertension, Abstract 1099Google Scholar
- 45.Sniderman, K.W., Sos, T.A. (1982). Percutaneous transluminal recanalisation and dilatation of totally occluded renal arteries. Radiology., 142, 607–10PubMedGoogle Scholar
- 46.Pickering, Tg., Sos, T.A., Laragh, J.H. (1984). Role of balloon dilatation in the treatment of renovascular hypertension. Am. J. Med. 11 (Suppl. 2A), 61–6Google Scholar
- 47.Shaw, A.B., Gopalka, S.K. (1982). Renal artery thrombosis caused by antihypertensive treatment. Br. Med. J. 285, 1617CrossRefGoogle Scholar
- 48.Hoefnagels, W.H.L., Thien, T. (1986). Renal artery occlusion in patients with renovascular hypertension treated with Captopril. Br. Med. J. 292, 24–5CrossRefGoogle Scholar
- 49.Hricik, D.E., Browning, P.J., Kopelman, R., Goorno, W.E., Madias, N.E., Dzau, V.J. (1983). Captopril-induced functional renal insufficiency in patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney. N. Engl. J. Med. 308, 373–6PubMedCrossRefGoogle Scholar
- 50.Watson, M.L., Bell, G.M., Muir, A.L., Buist, T.A.S., Kellett, R.J., Padfield, P.L. (1983). Captopril/diuretic combination in severe renovascular disease: a cautionary tale. Lancet., 2, 404–5PubMedCrossRefGoogle Scholar
- 51.Wenting, G.J., Tan-Tjiong, H.L., Derkx, F.H.M., de Bruyn, J.H.B. Man in’t Veld AJ and Schalekamp MADH. (1984). Split renal function after Captopril in unilateral renal artery stenosis. Br. Med. J. 288, 886–90CrossRefGoogle Scholar
- 52.Ishikawa, K. (1978). Natural history and classification of occlusive thrombo-arteropathy (Takayasu’s disease). Circulation., 57, 27–35PubMedCrossRefGoogle Scholar
- 53.Thurm, R.H., Alexander, J.C. (1984). Captopril in the treatment of scleroderma renal crisis. Arch. Intern. Med. 144, 733–5Google Scholar
- 54.Traub, Y.M., Shapiro, A.P., Rodman, G.P., Medsger, T.A., McDonald, R.H., Steen, U.D., Osial, T.A., Tolchin, S.F. (1983). Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Medicine., 62, 335–52PubMedCrossRefGoogle Scholar
- 55.Hodsman, G.P., Robertson, J.I.S. (1983). Captopril: five years on. Br. Med. J., 287, 851–2CrossRefGoogle Scholar
- 56.Todd, P.A., Heal, R.C. (1986). Enalapril: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension and congestive heart failure. Drugs., 31, 198–248PubMedCrossRefGoogle Scholar
- 57.Case, D.B., Wallace, J.M., Keim, J.H., Weber, M.A., Sealey, J.E., Laragh, J.H. (1977). Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme. N. Engl. J. Med. 296, 641–6PubMedCrossRefGoogle Scholar
- 58.Man in’t Veld, A.J., Schicht, I.M., Derkx, F.H.M., de Bruyn, J.H.B., Schalekamp, M.A.D.H. (1980). Effects of angiotensin-converting enzyme inhibitor (Captopril) on blood pressure. Br. Med. J. 280, 288–90CrossRefGoogle Scholar
- 59.Thurston, H., Swales, J.D. (1977). Blood-pressure response of nephrectomised hypertensive rats to converting enzyme inhibitors: evidence for persisting vascular renin activity. Clin. Sci. Mol. Med. 53, 299–304Google Scholar
- 60.Leading article. (1980). Captopril: benefits and risks in severe hypertension. Lancet., 2, 129–30Google Scholar
- 61.Dombey, S. (1983). Optimal dosage of Captopril in hypertension. Lancet., 1, 529PubMedCrossRefGoogle Scholar
- 62.Isles, C.G. Hodsman, G.P., Robertson, J.I.S. (1983). Side effects of Captopril. Lancet., 1, 355PubMedCrossRefGoogle Scholar
- 63.McFate Smith, W., Kulaga, S.F., Moncloa, F., Pingeon, R., Walker, J.F. (1984). Overall tolerance and safety of enalapril. J. Hypertension 2 (Suppl. 2), 113–17Google Scholar
- 64.Hodsman, G.P., Isles, C.G., Murray, G.D., Usherwood, T.P., Webb, D.J., Robertson, J.I.S. (1983). Factors related to first dose hypotensive effect of Captopril: prediction and treatment. Br. Med. J. 286, 832–4CrossRefGoogle Scholar
- 65.Webster, J., Newnham, D.M., Petrie, J.C. (1985). Initial dose of enalapril in hypertension. Br. Med. J. 290, 1623–4CrossRefGoogle Scholar
- 66.Webster, J., Newnham, D., Robb, O.J., Petrie, J.C. (1987). Antihypertensive effect of single doses of enalapril in hypertensive patients treated with bendro-fluazide. Br. J. Clin. Pharmacol. 23, 151–7PubMedCrossRefGoogle Scholar
- 67.Cleland, J.G.F., Dargie, HJ., McAlpine, H., Ball, S.G., Morton, J.J., Robertson, J.I.S., Ford, I. (1985). Severe hypotension after first doses of enalapril in heart failure. Br. Med. J. 291, 1309–12CrossRefGoogle Scholar
- 68.Curtis, J.J., Luke, R.G., Whelchel, J.D., Diethelm, A.G., James, P., Dustan, H.P. (1983). Inhibition of angiotensin-converting enzyme in renal transplant recipients with hypertension. N. Engl. J. Med. 308, 377–81PubMedCrossRefGoogle Scholar
- 69.Ghione, S., Fommei, E., Palombo, C., Giaconi, S., Mantovanelli, A., Ragawzini, A., and Palla, L. (1985–86). Kidney scintigraphy after ACE inhibition in the diagnosis of renovascular hypertension. Uraemia Invest., 9, 211–15Google Scholar
- 70.Silas, J.H., Klenka, Z., Solomon, S.A., Bone, J.M. (1983). Captopril induced reversible renal failure: a marker of renal artery stenosis affecting a solitary kidney. Br. Med. J. 286, 1702–3CrossRefGoogle Scholar
- 71.Enalapril in Hypertension Study Group (UK). Enalapril in essential hypertension: a comparative study with propranolol. (1984). Br. J. Clin. Pharmacol. 18, 51–6Google Scholar
- 72.Webster, J., Petrie, J.C., Robb, O.J., Trafford, J., Burgess, J., Richardson, P.J., Davidson, C., Fairhurst, G., Vandenberg, M.J., Cooper, W.D., Arr, S.M., Kimber, G. (1986). Enalapril in moderate to severe hypertension: a comparison with atenolol. Br. J. Clin. Pharmacol. 21, 489–95PubMedCrossRefGoogle Scholar
- 73.Croog, S.H., Lewis, S., Testa, M.A., Brown, B., Bulpitt, C.J., Jenkins, D., Kleman, G.L., Williams, G.H. (1986). The effects of antihypertensive therapy on the quality of life. N. Engl. J. Med. 314, 1657–64PubMedCrossRefGoogle Scholar
- 74.Tillman, D.M., Malatino, L.S., Cumming, A.M.M., Hodsman, G.P., Leckie, B.J., Lever, A.F., Morton, J.J., Webb, D.J., Robertson, J.I.S. (1984). Enalapril in hypertension with renal artery stenosis: long-term follow-up and effects on renal function. J. Hypertension 2 (Suppl. 2), 93–100Google Scholar
- 75.Nayler, W.G., Mclnnes, J., Swann, J.B., Carson, V., Lowe, T.E. (1967). Effects of propranolol, a beta-adrenergic antagonist, on blood flow in the coronary and other vascular fields. Am. Heart J. 73, 207–16PubMedCrossRefGoogle Scholar
- 76.Ibsen, H., Sederberg-Olsen, P. (1973). Changes in glomerular filtration rate during long-term treatment with propranolol in patients with arterial hypertension. Clin. Sci. 44, 129–34PubMedGoogle Scholar
- 77.Pritchard, B.N.C., Gillam, P.M.S. (1969). Treatment of hypertension with propranolol. Br. Med. J. 1, 7–16CrossRefGoogle Scholar
- 78.Warren, D.J., Swainson, C.P., Wright, N. (1974). Deterioration in renal function after beta-blockade in patients with chronic renal failure and hypertension. Br. Med. J. 2, 193–4PubMedCrossRefGoogle Scholar
- 79.Robb, O.J., Petrie, J.C., Webster, J., Harry, J. (1985). ICI 118551 does not reduce BP in hypertensive patients responsive to atenolol and propranolol. Br. J. Clin. Pharmacol. 19, 541–2Google Scholar
- 80.Deacon, S.P., Barnett, D. (1976). Comparison of atenolol and propranolol during insulin-induced hypoglycaemia. Br. Med. J. 2, 272–3PubMedCrossRefGoogle Scholar
- 81.Lager, I., Blomhme, G., Smith, H. (1979). Effect of cardioselective and nonselective –blockade on the hypoglycaemic response in insulin-dependent diabetes. Lancet., 1, 458–62PubMedCrossRefGoogle Scholar
- 82.Jeffers, T.A., Webster, J., Petrie, J.C., Barker, N.P. (1977). Atenolol once-daily in hypertension. Br. J. Clin. Pharmacol. 4, 523–7PubMedCrossRefGoogle Scholar
- 83.Webster, J., Petrie, J.C., Robb, O.J., Jamieson, M., Verschueren, J. (1985). A comparison of single doses of bucindolol and Oxprenolol in hypertensive patients. Br. J. Clin. Pharmacol. 20, 393–400PubMedCrossRefGoogle Scholar
- 84.Bannan, L.T. and Beevers, D.G. (1981). Emergency treatment of high blood pressure with oral atenolol. Br. Med. J., 282, 1757–8CrossRefGoogle Scholar
- 85.Pritchard, B.N.C. Beta-adrenoceptor blocking agents. In Abshagen, U. (Ed.) Clinical Pharmacology of Antianginal Drugs Handbook of Experimental Pharmacology, vol. 76, pp. 385–485. (Berlin: Springer)Google Scholar
- 86.Lowenthal, D.T. (1977). Pharmacokinetics of propranolol, quinidine, procainamide and lidocaine in chronic renal disease. Am. J. Med. 62, 532–8PubMedCrossRefGoogle Scholar
- 87.Johnsson, G., Regardh, C-G. (1976). Clinical pharmacokinetics of –adrenoceptor blocking drugs. Clin. Pharmacokinet. 1, 233–63PubMedCrossRefGoogle Scholar
- 88.Sorkin, E.M., Clissold, S.P., Brogden, R.N. (1985). Nifedipine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in ischaemic heart disease, hypertension and related cardiovascular disorders. Drugs., 30, 182–274PubMedCrossRefGoogle Scholar
- 89.Lee, S.M., Williams, R., Warnock, D., Emmett, M., Wolbach, R.A. (1986). The effects of nicardipine in hypertensive subjects with impaired renal function. Br. J. Clin. Pharmacol. 22, 297–306CrossRefGoogle Scholar
- 90.Diamond, J.R., Cheung, J.Y., Fang, L.S.T. (1984). Nifedipine-induced renal dysfunction. Am. J. Med. 77, 905–9PubMedCrossRefGoogle Scholar
- 91.Mroczek, W.J., Leibel, B.A., Davidov, M., Finnerty, F.A. (1971). The importance of the rapid administration of diazoxide in accelerated hypertension. N. Engl. J. Med. 285, 803–6CrossRefGoogle Scholar
- 92.Ledingham, J.G.G., Rajagopalan, B. (1979). Cerebral complications in the treatment of accelerated hypertension. Q. Med. J. 48, 25–41Google Scholar
- 93.Thien, T.A., Huysmans, F.T.M., Gerlag, P.G.G., Koene, R.A.P., Wijdeveld, P.G.A.B. (1979). Diazoxide infusion in severe hypertension and hypertensive crisis. Clin. Pharmacol. Ther. 25, 795–9PubMedGoogle Scholar
- 94.O’Malley, K., Velasco, M., Pruitt, A., McNay, J.L. (1975). Decreased plasma protein binding of diazoxide in uraemia. Clin. Pharmacol. Ther. 18, 53–8PubMedGoogle Scholar
- 95.Koch-Weser, J. (1976). Diazoxide. N. Engl. J. Med. 294, 1271–4PubMedCrossRefGoogle Scholar
- 96.Bennett, W.H., McDonald, W.J., Kuehnel, E., Hartnett, M.H., Porter, G.A. (1977). Do diuretics have antihypertensive properties independent of natriuresis? Clin. Pharmacol. Ther. 22, 499–504PubMedGoogle Scholar
- 97.Tobian, L. (1967). Why do thiazide diuretics lower blood pressure in essential hypertension? Annu. Rev. Pharmacol. 7, 399–408PubMedCrossRefGoogle Scholar
- 98.Webster, J. (1985). Interactions of NSAIDs with diuretics and β-blockers. Mechanisms and clinical implications. Drugs., 30, 32–41Google Scholar
- 99.Jones, B. and Nanra, R.S. (1979). Double-blind trial of antihypertensive effects of chlorothiazide in severe renal failure. Lancet., 2, 1258–60PubMedCrossRefGoogle Scholar
- 100.Ram, C.V.S., Garrett, B.N., Kaplan, W.M. (1981). Moderate sodium restriction and various diuretics in the treatment of hypertension: effect of potassium wastage and blood pressure control. Arch. Intern. Med. 141, 1015–19PubMedCrossRefGoogle Scholar
- 101.Weiner, I.M., Mudge, G.H. (1985). Diuretics and other agents employed in the mobilisation of edema fluid. In Gilman, A.G., Goodman, L.S., Rail, T.W., Murad, F. (Eds.) The Pharmacological Basis of Therapeutics, 7th Edn., pp. 887–907. New York: MacmillanGoogle Scholar
- 102.Sorkin, E.M., Brogden, R.N., Romankiewicz, J.A. (1984). Intravenous glyceryl trinitrate (Nitroglycerin). A review of its pharmacological properties and therapeutic efficacy. Drugs., 27, 45–80PubMedCrossRefGoogle Scholar
- 103.Cameron, H.A., Ramsay, L.E. (1984). The lupus syndrome induced by hydralazine: a common complication with lower dose treatment. Br. Med. J. 289, 410–12CrossRefGoogle Scholar
- 104.McAreavey, D., Ramsay, L.E., Latham, L., McLaren, A.D., Lorimer, A.R., Reid, J.L., Robertson, J.I.S., Robertson, M.P., Weir, R.J. (1984). “Third drug” trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic. Br. Med. J. 288, 106–10CrossRefGoogle Scholar
- 105.Talseth, T. (1976). Studies on hydralazine. II Elimination rate and steady-state concentration in patients with impaired renal function. Eur. J. Clin. Pharmacol. 10, 311–17PubMedCrossRefGoogle Scholar
- 106.Webster, J., Jeffers, T.A., Galloway, D.B., Petrie, J.C., Barker, N.P. (1977). Atenolol, methyldopa and chlorthalidone in moderate hypertension. Br. Med. J. 1, 76–7PubMedCrossRefGoogle Scholar
- 107.Myhre, E., Rugstad, H.E., Hansen, T. (1982). Clinical pharmacokinetics of methyldopa. Clin. Pharmacokinet. 7, 221–33PubMedCrossRefGoogle Scholar
- 108.Dargie, H.J., Dollery, C.T., Daniel, J. (1977). Minoxidil in resistant hypertension. Lancet., 2, 515–18PubMedCrossRefGoogle Scholar
- 109.Devine, B.L., Fife, R., Trust, P.M. (1977). Minoxidil for severe hypertension after failure of other hypotensive drugs. Br. Med. J. 2, 667–9PubMedCrossRefGoogle Scholar
- 110.Lowenthal, D.T., Affrime, M.B. (1980). Pharmacology and pharmacokinetics of minoxidil. J. Cardiovasc. Pharmacol. 2 (Suppl. 2), S93-S106PubMedCrossRefGoogle Scholar
- 111.Page, I.H., Corcoran, A.C., Dunstan, H.P., Koppanyi, T. (1955). Cardiovascular action of sodium nitroprusside in animals and hypertensive patients. Circulation., 11, 188–98PubMedCrossRefGoogle Scholar
- 112.Russell, G.I., Bing, R.F., Swales, J.D. (1978). Sodium nitroprusside and renovascular hypertension. Br. Med. J. 2, 14PubMedCrossRefGoogle Scholar
- 113.Stanaszek, W.F., Kellerman, D., Brogden, R.N. and Romankiewicz, J.A. (1983). Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure. Drugs., 25, 339–84PubMedCrossRefGoogle Scholar
- 114.Collier, J.C., Lorge, R.E., Robinson, B.F. (1978). Comparison of effects of tolmesoxide (RX 71107) diazoxide, hydralazine, prazosin, glyceryl trinitrate and sodium nitroprusside on forearm arteries and dorsal hand veins of man. Br. J. Clin. Pharmacol.5, 35–44PubMedCrossRefGoogle Scholar
- 115.Graham, R.M., Thornell, J.R., Gain, J.M., Bagnoli, C., Oates, H.F., Stokes, G.S. (1976). Prazosin: The first dose phenomenon. Br. Med. J. 2, 1293PubMedCrossRefGoogle Scholar
- 116.Velasco, M., Silva, H., Morillo, J., Pellieir, R., Urbina-Quintana, A., Hernandez-Pieretti, O. (1981). Effect of prazosin on blood lipids and on thyroid function in hypertensive patients. J. Cardiovasc. Pharmacol. 3, (Suppl. 3), 193–7Google Scholar
- 117.Stokes, G.S., Monaghan, J.C., Frost, G.W., MacCarthy, E.P. (1979). Responsiveness to prazosin in renal failure. Clin. Sci. 57, 383–5Google Scholar
- 118.Chin, D.K.F., Ho, A.K.C., Tse, C.Y. (1986). Neuropsychiatric complications related to use of prazosin in patients with renal failure. Br. Med. J. 293, 1347CrossRefGoogle Scholar
- 119.Lee, C.C., Marburg, T.C. (1984). Drug therapy in patients undergoing haemo-dialysis. Clinical pharmacokinetic considerations. Clin. Pharmacokinet. 9, 42–66CrossRefGoogle Scholar
- 120.Kuntzinger, H., Pouthier, D., Belluci, A. (1986). Treatment of hypertension with lisinopril in endstage renal failure. 11th Scientific Meeting of the International Society of Hypertension, Abstract No 532Google Scholar